These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 15049235)

  • 21. [A new drug which saves lives. Sepsis: chaos in the body--recent aspects of pathophysiology and therapy].
    Haas I
    Krankenpfl J; 2002; 40(10-12):310-4. PubMed ID: 12600015
    [No Abstract]   [Full Text] [Related]  

  • 22. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.
    Dhainaut JF; Laterre PF; Janes JM; Bernard GR; Artigas A; Bakker J; Riess H; Basson BR; Charpentier J; Utterback BG; Vincent JL;
    Intensive Care Med; 2003 Jun; 29(6):894-903. PubMed ID: 12712239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant human activated protein C.
    Hughes M
    Int J Antimicrob Agents; 2006 Aug; 28(2):90-4. PubMed ID: 16837170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated).
    Morris PE; Light RB; Garber GE
    Am J Surg; 2002 Dec; 184(6A Suppl):S19-24. PubMed ID: 12521614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activated protein C for sepsis.
    Toussaint S; Gerlach H
    N Engl J Med; 2009 Dec; 361(27):2646-52. PubMed ID: 20042756
    [No Abstract]   [Full Text] [Related]  

  • 26. The rise and fall of drotrecogin alfa (activated).
    Vincent JL
    Lancet Infect Dis; 2012 Sep; 12(9):649-51. PubMed ID: 22809884
    [No Abstract]   [Full Text] [Related]  

  • 27. Analysis of efficacy and safety of drotrecogin alfa (activated) in surgical patients, using an international integrated database.
    de Pont AC; Bakx R; Boermeester MA; Schultz MJ
    Surgery; 2007 Jun; 141(6):828-9. PubMed ID: 17560262
    [No Abstract]   [Full Text] [Related]  

  • 28. [Severe sepsis treated with activated protein C].
    Frøyshov S; Jacobsen D; Bjertnaes L; Flaatten H
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):779-81. PubMed ID: 15039807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk-benefit analysis for drotrecogin alfa (activated).
    Schein RM; Kinasewitz GT
    Am J Surg; 2002 Dec; 184(6A Suppl):S25-38. PubMed ID: 12521615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the use of activated protein C in the treatment of severe sepsis.
    Siegel JP
    N Engl J Med; 2002 Sep; 347(13):1030-4. PubMed ID: 12324563
    [No Abstract]   [Full Text] [Related]  

  • 31. Applying patient selection criteria for drotrecogin alfa therapy in practice.
    Wong-Beringer A; Liao C; Nguyen M; Pallares J
    Am J Health Syst Pharm; 2003 Jul; 60(13):1345-52. PubMed ID: 12901037
    [No Abstract]   [Full Text] [Related]  

  • 32. Xigris is withdrawn from the market. A 10 year odyssey.
    Suter PM
    Minerva Anestesiol; 2011 Dec; 77(12):1128-9. PubMed ID: 22134426
    [No Abstract]   [Full Text] [Related]  

  • 33. Drotrecogin alfa: excess mortality in the least severely ill patients.
    Prescrire Int; 2005 Aug; 14(78):145. PubMed ID: 16108104
    [No Abstract]   [Full Text] [Related]  

  • 34. Severe sepsis and therapy with activated protein C.
    Parrillo JE
    N Engl J Med; 2005 Sep; 353(13):1398-400. PubMed ID: 16192486
    [No Abstract]   [Full Text] [Related]  

  • 35. Drotrecogin alfa on trial.
    Tillotson GS
    Lancet Infect Dis; 2009 Jan; 9(1):2-3. PubMed ID: 19095188
    [No Abstract]   [Full Text] [Related]  

  • 36. Recombinant human activated protein C for severe sepsis.
    Kapur S; Kupfer Y; Tessler S
    N Engl J Med; 2001 Jul; 345(3):219-20; author reply 220-1. PubMed ID: 11463021
    [No Abstract]   [Full Text] [Related]  

  • 37. Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy.
    Sollet JP; Garber GE
    Am J Surg; 2002 Dec; 184(6A Suppl):S11-8. PubMed ID: 12521613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.
    Eichacker PQ; Danner RL; Suffredini AF; Cui X; Natanson C
    Crit Care Med; 2005 Oct; 33(10):2426-8. PubMed ID: 16215410
    [No Abstract]   [Full Text] [Related]  

  • 39. [Should patients with severe sepsis be treated with activated protein C?].
    Laake JH; Bergmann JB; Riddervold F; Bjørneklett A; Aukrust P; Frøland SS
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):782-4. PubMed ID: 15039808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa.
    Rice TW
    Vasc Health Risk Manag; 2006; 2(1):3-18. PubMed ID: 17319465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.